Phase 1/2 × Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2 Recruiting
188 enrolled
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
250 enrolled
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Phase 1/2 Recruiting
170 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Phase 1/2 Recruiting
220 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Phase 1/2 Recruiting
205 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
ELUCIDATE
Phase 1/2 Recruiting
230 enrolled
ODIN
Phase 1/2 Recruiting
43 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
29 enrolled
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Phase 1/2 Recruiting
242 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
862 enrolled
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/2 Recruiting
200 enrolled
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
130 enrolled
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Phase 1/2 Recruiting
300 enrolled
ModiFY
Phase 1/2 Recruiting
168 enrolled
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
76 enrolled
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Phase 1/2 Recruiting
50 enrolled
DENALI-1
Phase 1/2 Recruiting
240 enrolled
A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
68 enrolled
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Phase 1/2 Recruiting
80 enrolled
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Phase 1/2 Recruiting
96 enrolled
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
Phase 1/2 Recruiting
40 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
98 enrolled
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
29 enrolled
AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2 Recruiting
230 enrolled
RAPA-201 Therapy of Solid Tumors
Phase 1/2 Recruiting
37 enrolled
Study of NEO-201 in Solid Tumors Expansion Cohorts
Phase 1/2 Recruiting
121 enrolled
ADPORT-601
Phase 1/2 Recruiting
90 enrolled
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
140 enrolled
APT-CUBE
Phase 1/2 Recruiting
168 enrolled
RADIAN
Phase 1/2 Recruiting
34 enrolled
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
1,000 enrolled
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Phase 1/2 Recruiting
27 enrolled
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
523 enrolled
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Phase 1/2 Recruiting
71 enrolled
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Phase 1/2 Recruiting
160 enrolled
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
Phase 1/2 Recruiting
51 enrolled
AFAN
Phase 1/2 Recruiting
25 enrolled
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/2 Recruiting
316 enrolled
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/2 Recruiting
167 enrolled